Authors' recommendations: Glaucoma is a common condition that can lead to a loss of vision and eventually blindness. It is usually caused by increased pressure of fluid in the eye (ocular hypertension) when the fluid cannot drain away as well as usual. Glaucoma is usually treated with eye drops, however current treatments are not always effective, and patients may require laser treatment or eye surgery. Latanoprostene bunod is a new drug for the treatment of open-angle glaucoma and ocular hypertension. It is given as an eye drop taken once daily. Some studies have suggested latanoprostene bunod may be useful as a first line treatment and more studies are now aiming to show how well it works and that it is safe to use. If latanoprostene bunod is licensed for use in the UK, it could be a new treatment option for patients with glaucoma which may reduce pressure in the eye and reduce vision loss. If it is more effective than the current first line treatment, it could mean fewer eye drops and fewer visits to clinics would be needed.

Project Status: Completed

Year Published: 2016

URL for published report: http://www.hsric.nihr.ac.uk/topics/latanoprostene-bunod-for-open-angle-glaucoma-or-ocular-hypertension-first-line/

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: England, United Kingdom

Organisation Name: NIHR Horizon Scanning Centre

Contact Address: The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269

Contact Name: c.packer@bham.ac.uk

Contact Email: c.packer@bham.ac.uk

Copyright: NIHR Horizon Scanning Research&Intelligence Centre (NIHR HSRIC)